외음질 칸디다증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Vulvovaginal Candidiasis Treatment Market size is expected to reach USD 1.83 Billion in 2034 from USD 1.19 Billion (2025) growing at a CAGR of 4.82% during 2026-2034.

The Global Vulvovaginal Candidiasis Treatment Market is expanding due to the high incidence of fungal infections among women worldwide. Factors such as antibiotic overuse, hormonal changes, diabetes, and weakened immunity are contributing to increasing infection rates. Growing awareness regarding women's reproductive health is encouraging early diagnosis and treatment. Easy availability of over-the-counter antifungal medications is supporting market growth. Healthcare providers are also focusing on patient education to reduce recurrence rates.

Pharmaceutical companies are investing in improved drug formulations to enhance convenience and effectiveness. Single-dose oral antifungals and advanced topical creams are gaining popularity for their ease of use. Telemedicine platforms are improving consultation access, particularly in remote regions. Rising healthcare expenditure and insurance coverage are making treatments more accessible. Research into drug-resistant fungal strains is prompting the development of innovative therapies.

Future prospects remain positive with the introduction of probiotic-based preventive solutions and novel antifungal agents. Increased clinical trials focused on recurrent infections will strengthen product pipelines. Expanding healthcare infrastructure in developing regions will boost treatment adoption. Awareness campaigns emphasizing hygiene and preventive care will further support market growth. The sector is expected to maintain steady expansion driven by continuous innovation and rising healthcare awareness.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

By Route of Administration

• Oral
• Intravenous
• Topical

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Astellas Pharma Inc, Mycovia Pharmaceuticals Inc, Bayer AG, Basilea Pharmaceutica Ltd, Scynexis Inc, Grupo Ferrer Internacional SA, Pfizer Inc, Cadila Pharmaceuticals, BristolMyers Squibb Company, Glenmark Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Clotrimazole Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Nystatin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Fluconazole Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Ketoconazole Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Terbinafine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Terconazole Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Astellas Pharma Inc
  • 9.2.2 Mycovia Pharmaceuticals Inc
  • 9.2.3 Bayer AG
  • 9.2.4 Basilea Pharmaceutica Ltd
  • 9.2.5 Scynexis Inc
  • 9.2.6 Grupo Ferrer Internacional S.A
  • 9.2.7 Pfizer Inc
  • 9.2.8 Cadila Pharmaceuticals
  • 9.2.9 Bristol-Myers Squibb Company
  • 9.2.10 Glenmark Pharmaceuticals